• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. GSK to Sell Rights in Ofatumumab for Auto-Immune Indications to Novartis For Up to $1 Billion

    GSK to Sell Rights in Ofatumumab for Auto-Immune Indications to Novartis For Up to $1 Billion

  2. Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update

    Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update

  3. Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis

    Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis

  4. Pfizer Late-Stage Meningitis B Drug Studies Meet Endpoints

    Pfizer Late-Stage Meningitis B Drug Studies Meet Endpoints

  5. Research and Markets: Streptococcus Pneumoniae Infection - Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Streptococcus Pneumoniae Infection

    Research and Markets: Streptococcus Pneumoniae Infection - Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Streptococcus Pneumoniae Infection

  6. Research and Markets: Genital Herpes - API Insights 2015

    Research and Markets: Genital Herpes - API Insights 2015

  7. Glaxo Finds No Legionnaires' Risk at North Carolina Plant

    Glaxo Finds No Legionnaires' Risk at North Carolina Plant

  8. Research and Markets: Anti-Aging Products and Therapies Market Analysis 2015-2020 - Market Share and Market Size of Prominent Players Are Profiled

    Research and Markets: Anti-Aging Products and Therapies Market Analysis 2015-2020 - Market Share and Market Size of Prominent Players Are Profiled

  9. Andrew Hamer joins Cirrus Pharmaceuticals, a Kemwell Company as VP R&D

    Andrew Hamer joins Cirrus Pharmaceuticals, a Kemwell Company as VP R&D

  10. Avoid Medicare Advantage Plans

    GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.